Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q2 2024 revenue rises 14.6% to $528.1 million; diluted EPS $2.75

Positive Impact 3 of 5 earnings Written later

Medpace reported second quarter 2024 results on July 22, 2024, with revenue up 14.6% year over year and GAAP net income of $88.4 million, or $2.75 per diluted share, versus $1.93 a year earlier. The company also gave full-year 2024 guidance of $2.125 billion to $2.175 billion in revenue and $11.24 to $11.93 in diluted EPS, but net new business awards fell 4.1% in the quarter.

Key points

  • Q2 2024 revenue was $528.1 million, up 14.6% from $460.9 million; EBITDA rose 34.2% to $112.3 million.
  • Q2 2024 net new business awards were $551.0 million, down 4.1% from $574.8 million, for a net book-to-bill ratio of 1.04x.
  • 2024 guidance: revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, and diluted EPS of $11.24 to $11.93.
  • No share repurchases were made in Q2 2024; $308.8 million remained under the authorized program as of June 30, 2024.

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECJul 22, 2024, 4:16 PM ET
Accession number0001668397-24-000140

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.